Skip to main content

Table 4 Tumor response to HD IL-2

From: A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma

  Prior Ipi only n = 52 No prior ICB n = 276 Total n = 328
  n % n % n %
CR 1 1.92 9 3.26 10 3.05
PR 10 19.23 25 9.06 35 10.67
SD 15 28.85 74 26.81 89 27.13
PD 23 44.23 158 57.25 181 55.18
Missing 3 5.77 10 3.62 13 3.96
Total 52 100 276 100 328 100
  n % n % n %
CR + PR 11 21.15 34 12.32 45 13.72
CR + PR + SD 26 50 108 39.13 134 40.85